Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 1 · 25%High 1 · 25%

Death · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.12 [0.61, 2.06]
8 studies · 826 participants
Very low

Death at 6 months · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25 [0.35, 4.46]
1 study · 140 participants
Low

Death, all cause · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) showed no clear difference in death, all cause compared with azathioprine (AZA) (moderate certainty).

1 finding from 1 review

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients 2015 · Cochrane Headline outcomes only
RR 0.95 [0.7, 1.29]
16 studies · 2987 participants
Moderate

Graft loss censored for death · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) leads to lower graft loss, censored for death compared with azathioprine (AZA) (high certainty).

1 finding from 1 review